Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors

NCT06403436 is registered in ClinicalTrials.gov with TOLREMO therapeutics AG as lead sponsor.

NCT NCT06403436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06403436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
Lead sponsor
TOLREMO therapeutics AG
Phase
Phase 1
Overall status
Completed
Start date
November 7, 2023
Completion date
June 30, 2026
Enrollment
45 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

adult disease, adult solid tumor, advanced solid tumor, cancer, egfr, kras g12c, nsclc, squamous cell lung cancer